These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 20578910)

  • 1. Antiretroviral use among active injection-drug users: the role of patient-provider engagement and structural factors.
    Knowlton AR; Arnsten JH; Eldred LJ; Wilkinson JD; Shade SB; Bohnert AS; Yang C; Wissow LS; Purcell DW
    AIDS Patient Care STDS; 2010 Jul; 24(7):421-8. PubMed ID: 20578910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Individual, interpersonal, and structural correlates of effective HAART use among urban active injection drug users.
    Knowlton A; Arnsten J; Eldred L; Wilkinson J; Gourevitch M; Shade S; Dowling K; Purcell D;
    J Acquir Immune Defic Syndr; 2006 Apr; 41(4):486-92. PubMed ID: 16652058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users.
    Celentano DD; Galai N; Sethi AK; Shah NG; Strathdee SA; Vlahov D; Gallant JE
    AIDS; 2001 Sep; 15(13):1707-15. PubMed ID: 11546947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users.
    Wood E; Montaner JS; Yip B; Tyndall MW; Schechter MT; O'Shaughnessy MV; Hogg RS
    CMAJ; 2003 Sep; 169(7):656-61. PubMed ID: 14517122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severe food insecurity is associated with elevated unprotected sex among HIV-seropositive injection drug users independent of HAART use.
    Shannon K; Kerr T; Milloy MJ; Anema A; Zhang R; Montaner JS; Wood E
    AIDS; 2011 Oct; 25(16):2037-42. PubMed ID: 21811140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psychosocial determinants of adherence to highly active antiretroviral therapy among injection drug users in Vancouver.
    Kerr T; Palepu A; Barness G; Walsh J; Hogg R; Montaner J; Tyndall M; Wood E
    Antivir Ther; 2004 Jun; 9(3):407-14. PubMed ID: 15259903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microsocial environmental influences on highly active antiretroviral therapy outcomes among active injection drug users: the role of informal caregiving and household factors.
    Knowlton AR; Arnsten JH; Gourevitch MN; Eldred L; Wilkinson JD; Rose CD; Buchanan A; Purcell DW;
    J Acquir Immune Defic Syndr; 2007 Nov; 46 Suppl 2():S110-9. PubMed ID: 18089980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy.
    Wang C; Vlahov D; Galai N; Bareta J; Strathdee SA; Nelson KE; Sterling TR
    J Infect Dis; 2004 Sep; 190(6):1046-54. PubMed ID: 15319852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ongoing drug use and outcomes from highly active antiretroviral therapy among injection drug users in a Canadian setting.
    Krüsi A; Milloy MJ; Kerr T; Zhang R; Guillemi S; Hogg R; Montaner J; Wood E
    Antivir Ther; 2010; 15(5):789-96. PubMed ID: 20710061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV treatment as prevention among injection drug users.
    Wood E; Milloy MJ; Montaner JS
    Curr Opin HIV AIDS; 2012 Mar; 7(2):151-6. PubMed ID: 22227587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Temporal trends in highly active antiretroviral therapy initiation among injection drug users in Baltimore, Maryland, 1996-2008.
    Mehta SH; Kirk GD; Astemborski J; Galai N; Celentano DD
    Clin Infect Dis; 2010 Jun; 50(12):1664-71. PubMed ID: 20450418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Highly active antiretroviral therapy and survival in HIV-infected injection drug users.
    Wood E; Hogg RS; Lima VD; Kerr T; Yip B; Marshall BD; Montaner JS
    JAMA; 2008 Aug; 300(5):550-4. PubMed ID: 18677027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of injecting drug use on response to highly active antiretroviral treatment in HIV-1-infected patients: a nationwide population-based cohort study.
    Larsen MV; Omland LH; Gerstoft J; Røge BT; Larsen CS; Pedersen G; Obel N; Kronborg G
    Scand J Infect Dis; 2010 Dec; 42(11-12):917-23. PubMed ID: 20840000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in sexual and drug-related risk behavior following antiretroviral therapy initiation among HIV-infected injection drug users.
    Fu TC; Westergaard RP; Lau B; Celentano DD; Vlahov D; Mehta SH; Kirk GD
    AIDS; 2012 Nov; 26(18):2383-91. PubMed ID: 23079804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic factors for survival differ according to CD4+ cell count among HIV-infected injection drug users: pre-HAART and HAART eras.
    Galai N; Vlahov D; Bareta JC; Wang C; Cohn S; Sterling TR
    J Acquir Immune Defic Syndr; 2005 Jan; 38(1):74-81. PubMed ID: 15608529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increase in sexual risk behavior associated with immunologic response to highly active antiretroviral therapy among HIV-infected injection drug users.
    Tun W; Gange SJ; Vlahov D; Strathdee SA; Celentano DD
    Clin Infect Dis; 2004 Apr; 38(8):1167-74. PubMed ID: 15095224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy.
    Palepu A; Tyndall MW; Joy R; Kerr T; Wood E; Press N; Hogg RS; Montaner JS
    Drug Alcohol Depend; 2006 Sep; 84(2):188-94. PubMed ID: 16542797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incarceration predicts virologic failure for HIV-infected injection drug users receiving antiretroviral therapy.
    Westergaard RP; Kirk GD; Richesson DR; Galai N; Mehta SH
    Clin Infect Dis; 2011 Oct; 53(7):725-31. PubMed ID: 21890777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
    Palepu A; Tyndall MW; Chan K; Wood E; Montaner JS; Hogg RS
    Antivir Ther; 2004 Oct; 9(5):713-9. PubMed ID: 15535408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonstructured treatment interruptions among injection drug users in Baltimore, MD.
    Kavasery R; Galai N; Astemborski J; Lucas GM; Celentano DD; Kirk GD; Mehta SH
    J Acquir Immune Defic Syndr; 2009 Apr; 50(4):360-6. PubMed ID: 19214124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.